Femasys issued U.S. patent covering FemBloc device

Femasys (FEMY) announces that the United States Patent and Trademark Office issued U.S. Patent No. 12,12796 covering FemBloc permanent birth control. This further strengthens Femasys’ intellectual property position and coverage for FemBloc, the Company’s leading therapeutic product candidate. The issued patent has an anticipated expiration in 2039 at the earliest. Femasys intends to continue to prosecute additional patent applications to further enhance its existing patent portfolio protecting FemBloc, along with the Company’s existing available therapeutic product, FemaSeed intratubal insemination for infertility treatment, and diagnostic products, FemVue, FemCath, FemCerv, and FemChec.